Cargando…

Path analysis of biomarkers for cognitive decline in early Parkinson’s disease

Clinical and biochemical diversity of Parkinson’s disease (PD) and numerous demographic, clinical, and pathological measures influencing cognitive function and its decline in PD create problems with the determination of effects of individual measures on cognition in PD. This is particularly the case...

Descripción completa

Detalles Bibliográficos
Autores principales: Gramotnev, Dmitri K., Gramotnev, Galina, Gramotnev, Alexandra, Summers, Mathew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106174/
https://www.ncbi.nlm.nih.gov/pubmed/35560326
http://dx.doi.org/10.1371/journal.pone.0268379
_version_ 1784708219999879168
author Gramotnev, Dmitri K.
Gramotnev, Galina
Gramotnev, Alexandra
Summers, Mathew J.
author_facet Gramotnev, Dmitri K.
Gramotnev, Galina
Gramotnev, Alexandra
Summers, Mathew J.
author_sort Gramotnev, Dmitri K.
collection PubMed
description Clinical and biochemical diversity of Parkinson’s disease (PD) and numerous demographic, clinical, and pathological measures influencing cognitive function and its decline in PD create problems with the determination of effects of individual measures on cognition in PD. This is particularly the case where these measures significantly interrelate with each other producing intricate networks of direct and indirect effects on cognition. Here, we use generalized structural equation modelling (GSEM) to identify and characterize significant paths for direct and indirect effects of 14 baseline measures on global cognition in PD at baseline and at 4 years later. We consider 269 drug-naïve participants from the Parkinson’s Progression Marker Initiative database, diagnosed with idiopathic PD and observed for at least 4 years after baseline. Two GSEM networks are derived, highlighting the possibility of at least two different molecular pathways or two different PD sub-types, with either CSF p-tau181 or amyloid beta (1–42) being the primary protein variables potentially driving progression of cognitive decline. The models provide insights into the interrelations between the 14 baseline variables, and determined their total effects on cognition in early PD. High CSF amyloid concentrations (> 500 pg/ml) are associated with nearly full protection against cognitive decline in early PD in the whole range of baseline age between 40 and 80 years, and irrespectively of whether p-tau181 or amyloid beta (1–42) are considered as the primary protein variables. The total effect of depression on cognition is shown to be strongly amplified by PD, but not at the time of diagnosis or at prodromal stages. CSF p-tau181 protein could not be a reliable indicator of cognitive decline because of its significantly heterogeneous effects on cognition. The outcomes will enable better understanding of the roles of the clinical and pathological measures and their mutual effects on cognition in early PD.
format Online
Article
Text
id pubmed-9106174
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-91061742022-05-14 Path analysis of biomarkers for cognitive decline in early Parkinson’s disease Gramotnev, Dmitri K. Gramotnev, Galina Gramotnev, Alexandra Summers, Mathew J. PLoS One Research Article Clinical and biochemical diversity of Parkinson’s disease (PD) and numerous demographic, clinical, and pathological measures influencing cognitive function and its decline in PD create problems with the determination of effects of individual measures on cognition in PD. This is particularly the case where these measures significantly interrelate with each other producing intricate networks of direct and indirect effects on cognition. Here, we use generalized structural equation modelling (GSEM) to identify and characterize significant paths for direct and indirect effects of 14 baseline measures on global cognition in PD at baseline and at 4 years later. We consider 269 drug-naïve participants from the Parkinson’s Progression Marker Initiative database, diagnosed with idiopathic PD and observed for at least 4 years after baseline. Two GSEM networks are derived, highlighting the possibility of at least two different molecular pathways or two different PD sub-types, with either CSF p-tau181 or amyloid beta (1–42) being the primary protein variables potentially driving progression of cognitive decline. The models provide insights into the interrelations between the 14 baseline variables, and determined their total effects on cognition in early PD. High CSF amyloid concentrations (> 500 pg/ml) are associated with nearly full protection against cognitive decline in early PD in the whole range of baseline age between 40 and 80 years, and irrespectively of whether p-tau181 or amyloid beta (1–42) are considered as the primary protein variables. The total effect of depression on cognition is shown to be strongly amplified by PD, but not at the time of diagnosis or at prodromal stages. CSF p-tau181 protein could not be a reliable indicator of cognitive decline because of its significantly heterogeneous effects on cognition. The outcomes will enable better understanding of the roles of the clinical and pathological measures and their mutual effects on cognition in early PD. Public Library of Science 2022-05-13 /pmc/articles/PMC9106174/ /pubmed/35560326 http://dx.doi.org/10.1371/journal.pone.0268379 Text en © 2022 Gramotnev et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Gramotnev, Dmitri K.
Gramotnev, Galina
Gramotnev, Alexandra
Summers, Mathew J.
Path analysis of biomarkers for cognitive decline in early Parkinson’s disease
title Path analysis of biomarkers for cognitive decline in early Parkinson’s disease
title_full Path analysis of biomarkers for cognitive decline in early Parkinson’s disease
title_fullStr Path analysis of biomarkers for cognitive decline in early Parkinson’s disease
title_full_unstemmed Path analysis of biomarkers for cognitive decline in early Parkinson’s disease
title_short Path analysis of biomarkers for cognitive decline in early Parkinson’s disease
title_sort path analysis of biomarkers for cognitive decline in early parkinson’s disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106174/
https://www.ncbi.nlm.nih.gov/pubmed/35560326
http://dx.doi.org/10.1371/journal.pone.0268379
work_keys_str_mv AT gramotnevdmitrik pathanalysisofbiomarkersforcognitivedeclineinearlyparkinsonsdisease
AT gramotnevgalina pathanalysisofbiomarkersforcognitivedeclineinearlyparkinsonsdisease
AT gramotnevalexandra pathanalysisofbiomarkersforcognitivedeclineinearlyparkinsonsdisease
AT summersmathewj pathanalysisofbiomarkersforcognitivedeclineinearlyparkinsonsdisease